Canakinumab for patients with Still’s disease refractory to anakinra and tocilizumab (adults and children 2 years and over)

Document first published:
Page updated:
Topic:
Publication type:

Canakinumab is not recommended to be available as a routine commissioning treatment option for adults and children 2 years and over with Still’s disease refractory to treatment with (or do not tolerate) anakinra and tocilizumab.

This policy is restricted to certain age groups to reflect the marketing authorisation of canakinumab.

Document

Clinical commissioning policy: canakinumab for patients with Still’s disease refractory to anakinra and tocilizumab (adults and children 2 years and over)

Clinical commissioning policy: canakinumab for patients with Still’s disease refractory to anakinra and tocilizumab (adults and children 2 years and over)

  • PDF
  • 155 KB
  • 5 pages

Summary

Published 19 January 2026.

Document

Clinical Panel report: canakinumab for patients with Still’s disease refractory to anakinra and tocilizumab (adults and children 2 years and over)

Clinical Panel report: canakinumab for patients with Still’s disease refractory to anakinra and tocilizumab (adults and children 2 years and over)

  • PDF
  • 177 KB
  • 3 pages

Summary

Published 19 January 2026.

Document

Clinical Priorities Advisory Group: canakinumab for patients with Still’s disease refractory to anakinra and tocilizumab (adults and children 2 years and over)

Clinical Priorities Advisory Group: canakinumab for patients with Still’s disease refractory to anakinra and tocilizumab (adults and children 2 years and over)

  • PDF
  • 214 KB
  • 14 pages

Summary

Published 19 January 2026.

Document

Engagement report: canakinumab for patients with Still’s disease refractory to anakinra and tocilizumab (adults and children 2 years and over)

Engagement report: canakinumab for patients with Still’s disease refractory to anakinra and tocilizumab (adults and children 2 years and over)

  • PDF
  • 307 KB
  • 9 pages

Summary

Published 19 January 2026.

Document

NHS England evidence review: canakinumab for patients with adult-onset Still’s disease (AOSD) refractory to anakinra and tocilizumab

NHS England evidence review: canakinumab for patients with adult-onset Still’s disease (AOSD) refractory to anakinra and tocilizumab

  • PDF
  • 554 KB
  • 50 pages

Summary

Published 19 January 2026.

Document

NHS England evidence review: canakinumab for patients with systemic-onset juvenile idiopathic arthritis (SJIA) refractory to anakinra and tocilizumab

NHS England evidence review: canakinumab for patients with systemic-onset juvenile idiopathic arthritis (SJIA) refractory to anakinra and tocilizumab

  • PDF
  • 630 KB
  • 56 pages

Summary

Published 19 January 2026.